Drugs /

anti-muc1 car-transduced autologous t-lymphocytes

Back to Drugs List

Overview

NCI Definition [1]:
Autologous T-lymphocytes transduced with a retroviral vector expressing a chimeric antigen receptor (CAR) consisting of a single chain variable fragment (scFv) against the human tumor-associated epithelial antigen mucin 1 (MUC1), with potential immunomodulating and antineoplastic activities. Autologous PBLs from a patient with MUC1-positive cancer are transduced with a retroviral vector that encodes the CAR gene specific for MUC1. After expansion in culture and reintroduction into the patient, anti-MUC1 CAR-transduced autologous T-lymphocytes target and induce selective toxicity in MUC1-expressing tumor cells. MUC-1 is a human, hypoglycosylated tumor-associated antigen (TAA) overexpressed by epithelial cancer cells.

Clinical Trials

View Clinical Trials for anti-muc1 car-transduced autologous t-lymphocytes

Anti-muc1 car-transduced autologous t-lymphocytes has been investigated in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials investigating anti-muc1 car-transduced autologous t-lymphocytes, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for anti-muc1 car-transduced autologous t-lymphocytes clinical trials.

Breast carcinoma, fallopian tube carcinoma, and multiple myeloma are the most common diseases being investigated in anti-muc1 car-transduced autologous t-lymphocytes clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Anti-Muc1 Car-Transduced Autologous T-Lymphocytes
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating anti-muc1 car-transduced autologous t-lymphocytes and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
anti-muc1 car-transduced autologous t cells, anti-muc1 autologous car t cells, anti-mucin1 autologous car t cells, anti-muc1 car-transduced autologous t cells, anti-muc1 car-transduced autologous t lymphocytes, anti-mucin1 autologous car t cells, anti-muc1 car t cells
NCIT ID [1]:
C124646

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.